Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $26.60.

Several equities research analysts recently issued reports on the company. Weiss Ratings cut Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 25th. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and lifted their price objective for the company from $27.00 to $28.00 in a report on Wednesday, August 19th. Wall Street Zen downgraded Pediatrix Medical Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday. UBS Group increased their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Finally, Truist Financial raised their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jennison Associates LLC acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter valued at $768,000. Burney Co. bought a new position in Pediatrix Medical Group in the first quarter valued at about $1,129,000. Fifth Third Bancorp raised its position in Pediatrix Medical Group by 7,643.2% in the first quarter. Fifth Third Bancorp now owns 62,333 shares of the company’s stock valued at $1,333,000 after purchasing an additional 61,528 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Pediatrix Medical Group by 12.9% during the first quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock valued at $32,776,000 after purchasing an additional 174,600 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Pediatrix Medical Group by 139.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 69,069 shares of the company’s stock valued at $1,493,000 after purchasing an additional 40,176 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $27.03 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $2.20 billion, a P/E ratio of 12.93 and a beta of 0.64. Pediatrix Medical Group has a 12-month low of $15.69 and a 12-month high of $27.94. The firm has a 50-day moving average price of $26.32 and a two-hundred day moving average price of $23.38.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The firm had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. During the same quarter in the prior year, the business posted $0.53 EPS. The business’s revenue was up 4.1% compared to the same quarter last year. Analysts anticipate that Pediatrix Medical Group will post 2.17 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.